Based on convincing results of EMPA-REG OUTCOME [38] study and other similar trials [39], 2019 ESC Guidelines on DM, pre-DM and cardiovascular diseases (CVD) recommended the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients with T2DM and CVD or at high/very high cardiovascular (CV) risk to reduce CV events. This evidence concerns the gene SLC5A2 and cardiovascular disorder.